Core Insights - CEL-SCI Corporation is scheduled to present its strategic roadmap for Multikine at the LD Micro "Main Event" Investor Conference on October 21, 2025 [1][2] Company Overview - CEL-SCI Corporation is a clinical stage cancer immunotherapy company focused on enhancing the immune system's ability to target tumors before surgical interventions [3] - The company operates in Vienna, Virginia, and near Baltimore, Maryland [5] Product Information - Multikine (Leukocyte Interleukin, Injection) is a first-line cancer therapy that has been administered to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck [4] - The FDA has approved CEL-SCI to conduct a confirmatory Registration Study for Multikine, which will enroll 212 patients with newly diagnosed locally advanced resectable head and neck cancer [4] - The target patient population for this study is estimated to represent about 100,000 patients annually [4]

Core Viewpoint - CEL-SCI Corporation is set to present its strategic roadmap for the development of Multikine at the LD Micro "Main Event" Investor Conference on October 21, 2025 [1][2]. Company Overview - CEL-SCI Corporation is a clinical stage cancer immunotherapy company focused on enhancing the immune system's ability to target tumors before surgical interventions [3]. - The company operates in Vienna, Virginia, and near Baltimore, Maryland [5]. Product Information - Multikine (Leukocyte Interleukin, Injection) is a first-line cancer therapy that has been administered to over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck [4]. - A completed randomized controlled Phase 3 study involving 928 patients has led to FDA approval for a confirmatory Registration Study, which will enroll 212 patients with newly diagnosed locally advanced resectable head and neck cancer [4]. - The target patient population for this study is approximately 100,000 patients annually, specifically those with no lymph node involvement and low PD-L1 tumor expression [4].